ASX - Delayed Quote AUD

HeraMED Limited (HMD.AX)

0.0170 0.0000 (0.00%)
At close: April 2 at 3:50 PM GMT+11

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Dr. Ronald Peter Weinberger AIMM, BSc (Hons), Ph.D. Executive Chairman 247.7k -- --
Mr. Ido Toronchik Chief Financial Officer -- -- 1983
Henry Jordan Head of Investor Relations -- -- --
Mr. Ariel Laden Vice President of Marketing -- -- --
Mr. Keith Koby BSEET, MBA President of North America -- -- --
Mr. Jonathan Hart B.Com., L.L.B. Company Secretary -- -- 1984

HeraMED Limited

4 Hazoran Street
POB 8576
Netanya, 4250604
Israel
https://www.hera-med.com
Sector: 
Healthcare
Industry: 
Medical Devices

Description

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.

Corporate Governance

HeraMED Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers